Target Identification Is Becoming the New Battleground for AI in Drug Discovery
Nature’s latest framing of AI in target identification underscores a key shift: the field is moving from flashy model demos to the hard problem of choosing the right biological target. That is where AI will be judged most harshly, and where it may matter most.
Target identification is one of the most consequential steps in drug development, and it is also one of the least forgiving. If AI helps teams choose the wrong target more efficiently, it only accelerates failure. If it helps pick the right target earlier, the downstream payoff can be enormous.
Nature’s attention to this area reflects a maturing conversation about AI in biology. The emphasis is shifting away from whether models can generate plausible outputs and toward whether they can support better scientific judgment. That is a much higher bar, but also a much more meaningful one.
In practice, target identification requires integrating evidence across genetics, biology, disease context, and translational feasibility. AI can help by finding patterns humans miss, but only if the underlying data are robust and the model is used as part of a disciplined research process. This is where domain expertise remains essential.
The larger lesson is that AI’s biggest impact in drug discovery may come not from automating chemistry alone, but from improving upstream decisions that determine whether a program is worth pursuing. That makes target selection a strategic, not just technical, frontier.